表紙
市場調查報告書

骨髓纖維化治療藥的全球市場:2018年∼2022年

Global Myelofibrosis Therapeutics Market 2018-2022

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 773824
出版日期 內容資訊 英文 106 Pages
訂單完成後即時交付
價格
骨髓纖維化治療藥的全球市場:2018年∼2022年 Global Myelofibrosis Therapeutics Market 2018-2022
出版日期: 2018年12月21日內容資訊: 英文 106 Pages
簡介

骨髓纖維化,是罕見變異的費城染色體陰性骨髓增生性腫瘤(MPN)之一。唯一獲得FDA認證的藥物治療是JAKAVI / JAKAFI(Ruxolitinib)。它是一種有效的口服JAK1 / JAK2抑製劑,用於治療骨髓纖維化患者。HSCT療法有還有配對捐贈者不合適的缺點。也有其他療法,包括輸血和雄激素療法,只能減少骨髓纖維化的貧血副作用。因此,在目前可用的所有治療中,沒有一種是可以完全幫助根除疾病的理想治療方法。Technavio的分析師預測,到2022年,骨髓纖維化治療市場的年複合成長率將超過7%。

本報告提供全球骨髓纖維化治療藥市場相關調查分析,市場規模與成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 報告的範圍

第3章 調查方法

第4章 市場情形

  • 市場生態系統
  • 市場特徵
  • 市場區隔分析

第5章 開發平台分析

  • 開發平台分析

第6章 市場規模

市場定義

  • 市場規模(2017年)
  • 市場規模及預測(2017年∼2022年)

第7章 波特的五力分析

  • 買主談判力
  • 供應商談判力
  • 新加入廠商的威脅
  • 替代品的威脅
  • 競爭對手的威脅
  • 市場情況

第8章 市場區隔:治療的各類型

  • 市場區隔:治療的各類型
  • 治療的各類型比較:市場規模及預測(2017年∼2022年)
  • 藥物療法
  • 輸血
  • HSCT
  • 雄激素療法
  • 市場機會:治療的各類型

第9章 客戶形勢

第10章 地區形勢

  • 各地區市場區隔
  • 地區比較:市場規模及預測(2017年∼2022年)
  • 南北美洲
  • 歐洲、中東、非洲地區
  • 亞太地區
  • 市場機會

第11章 決策架構

第12章 成長要素與課題

  • 市場成長要素
  • 市場課題

第13章 市場趨勢

  • 對於HSCT骨髓纖維化的唯一治療方法的選項
  • 羥基尿素,免疫調節劑,類固醇等高用量非適應症處方

第14章 業者情勢

  • 概要
  • 創造性破壞狀況

第15章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • Bristol-Myers Squibb
  • CELGENE
  • Incyte
  • Novartis

第16章 附錄

  • 簡稱的清單
目錄
Product Code: IRTNTR23859

About this market

Myelofibrosis is as Philadelphia chromosome- negative myeloproliferative neoplasm (MPN), a rare mutation. The only FDA approved drug therapy is JAKAVI/JAKAFI (Ruxolitinib). It is a potent oral JAK1/ JAK2 inhibitor used for treating the patients with myelofibrosis. HSCT therapy is also having disadvantages regarding the unavailability of matching donors. Other therapies, including the transfusion and androgen therapy, merely reduce the anemic side effects of myelofibrosis. Thus, among all treatments available at present, none can be considered as an ideal one that can completely help in eradicating the disease. Technavio's analysts have predicted that the myelofibrosis therapeutics market will register a CAGR of more than 7% by 2022.

Market Overview

Increasing number of companies entering the myelofibrosis segment

Before the launch of JAKAVI/JAKAFI, there were very few companies investing in the R&D of myelofibrosis therapies.

Limited market size as myelofibrosis is a rare disorder

The number of available therapies including the orphan drugs for this disorder is very limited. The treatment options employed by physicians are mostly the off- label drugs that are meant for the treatment of some other condition or the blood transfusion or stem cell transplantation.

For the detailed list of factors that will drive and challenge the growth of the myelofibrosis therapeutics market during the 2018-2022, view our report.

Competitive Landscape

The global myelofibrosis therapeutics market is extremely concentrated. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 05: PIPELINE ANALYSIS

  • Pipeline analysis

PART 06: MARKET SIZING

Market definition

  • Market sizing 2017
  • Market size and forecast 2017-2022

PART 07: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 08: MARKET SEGMENTATION BY TYPE OF TREATMENT

  • Segmentation by type of treatment
  • Comparison by type of treatment
  • Drug therapy - Market size and forecast 2017-2022
  • Blood transfusion - Market size and forecast 2017-2022
  • HSCT - Market size and forecast 2017-2022
  • Androgen Therapy - Market size and forecast 2017-2022
  • Market opportunity by type of treatment

PART 09: CUSTOMER LANDSCAPE

PART 10: REGIONAL LANDSCAPE

  • Geographical segmentation
  • Regional comparison
  • Americas - Market size and forecast 2017-2022
  • EMEA - Market size and forecast 2017-2022
  • APAC - Market size and forecast 2017-2022
  • Market opportunity

PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 13: MARKET TRENDS

  • HSCT is the only curative option for myelofibrosis
  • High off-label prescription including hydroxyurea, Immunomodulators, and steroids

PART 14: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 15: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bristol-Myers Squibb
  • CELGENE
  • Incyte
  • Novartis

PART 16: APPENDIX

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Global oncology therapeutics market
  • Exhibit 02: Global oncology therapeutics market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Pipeline molecules for myelofibrosis 2017-2018
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2017
  • Exhibit 08: Validation techniques employed for market sizing 2017
  • Exhibit 09: Global - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 10: Global - Year-over-year growth 2018-2022 (%)
  • Exhibit 11: Five forces analysis 2017
  • Exhibit 12: Five forces analysis 2022
  • Exhibit 13: Bargaining power of buyers
  • Exhibit 14: Bargaining power of suppliers
  • Exhibit 15: Threat of new entrants
  • Exhibit 16: Threat of substitutes
  • Exhibit 17: Threat of rivalry
  • Exhibit 18: Market condition - Five forces 2017
  • Exhibit 19: Type of treatment - Market share 2017-2022 (%)
  • Exhibit 20: Comparison by type of treatment
  • Exhibit 21: Drug therapy - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 22: JAKAVI/JAKAFI sales from 2015-2017
  • Exhibit 23: Drug therapy - Year-over-year growth 2018-2022 (%)
  • Exhibit 24: *Blood transfusion - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 25: Blood transfusion - Year-over-year growth 2018-2022 (%)
  • Exhibit 26: HSCT - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 27: HSCT - Year-over-year growth 2018-2022 (%)
  • Exhibit 28: Androgen therapy - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 29: Androgen Therapy - Year-over-year growth 2018-2022 (%)
  • Exhibit 30: Market opportunity by type of treatment
  • Exhibit 31: Customer landscape
  • Exhibit 32: Global - Market share by geography 2017-2022 (%)
  • Exhibit 33: Regional comparison
  • Exhibit 34: Americas - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 35: Americas - Year-over-year growth 2018-2022 (%)
  • Exhibit 36: Top 3 countries in Americas
  • Exhibit 37: EMEA - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 38: EMEA - Year-over-year growth 2018-2022 (%)
  • Exhibit 39: Top 3 countries in EMEA
  • Exhibit 40: APAC - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 41: APAC - Year-over-year growth 2018-2022 (%)
  • Exhibit 42: Top 3 countries in APAC
  • Exhibit 43: Market opportunity
  • Exhibit 44: Vendor landscape
  • Exhibit 45: Landscape disruption
  • Exhibit 46: Vendor classification
  • Exhibit 47: Market positioning of vendors
  • Exhibit 48: Bristol-Myers Squibb - Overview
  • Exhibit 49: Bristol-Myers Squibb - Business segments
  • Exhibit 50: Bristol-Myers Squibb - Organizational developments
  • Exhibit 51: Bristol-Myers Squibb - Geographic focus
  • Exhibit 52: Bristol-Myers Squibb - Key offerings
  • Exhibit 53: Bristol-Myers Squibb - Key customers
  • Exhibit 54: CELGENE - Overview
  • Exhibit 55: CELGENE - Business segments
  • Exhibit 56: CELGENE - Organizational developments
  • Exhibit 57: CELGENE - Geographic focus
  • Exhibit 58: CELGENE - Key offerings
  • Exhibit 59: CELGENE - Key customers
  • Exhibit 60: Incyte - Overview
  • Exhibit 61: Incyte - Business segments
  • Exhibit 62: Incyte - Organizational developments
  • Exhibit 63: Incyte - Geographic focus
  • Exhibit 64: Incyte - Key offerings
  • Exhibit 65: Incyte - Key customers
  • Exhibit 66: Novartis - Overview
  • Exhibit 67: Novartis - Business segments
  • Exhibit 68: Novartis - Organizational developments
  • Exhibit 69: Novartis - Geographic focus
  • Exhibit 70: Novartis - Segment focus
  • Exhibit 71: Novartis - Key offerings
  • Exhibit 72: Novartis - Key customers